The development and commercialization agreement for certolizumab pegol in psoriasis has been closed, announced Dermira and Ucb, in order to reflect both companies’ strategic priorities. Following positive Phase 3 clinical trial results, the companies announced U.S. and EU regulatory submissions for the treatment of moderate-to-severe chronic plaque psoriasis in July of this year. Pending regulatory approval, Ucb remains committed to commercializing the product in psoriasis worldwide. Both parties will undertake a transfer of data and Dermira will not participate in any future development or commercialization activities.